# ICARUS-LUNG01: HCP commentary report

> 59 verified statements (31 from clinicians verified by NPI or staff page) from 25 commentary sources · 8 findings · updated Oct 31, 2026

## Report

- Trial: Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy
- NCT ID: NCT04940325
- Registry: https://clinicaltrials.gov/study/NCT04940325
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: datopotamab deruxtecan
- Indication: advanced and/or unresectable non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: aaa5f92eedb9cefd0b4d0abd0314c226c7132ebcbface68df54030175de887d6

## Counts

- HCP commentary sources screened: 55
- Sources cited by verified statements: 25
- Verified statements: 59
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 31
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 18
- Voices cited: 16
- Cited voices identity-verified: 14
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ICARUS-LUNG01 asks whether datopotamab deruxtecan shrinks tumors in previously treated advanced non-small cell lung cancer and which biomarkers could guide treatment. Commentary comes from X posts, a podcast featuring a medical oncologist, and a YouTube discussion. The discussion turns on datopotamab deruxtecan’s unresolved later-line role, whether target expression captures ADC payload biology, and how to weigh toxicity despite targeted delivery. The sources place the ICARUS-LUNG01 phase 2 results at ASCO 2024.

## Open Medical Affairs question

What evidence would justify histology- and biomarker-informed selection, sequencing or alternative-treatment choices without overstating the efficacy or understating toxicity?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Histology shapes the efficacy reading, but replication is not universally viewed as new information
- F2. Two speakers emphasize toxicity despite targeted delivery
- F3. TROP2 expression is interpreted as predictive, weakly associated or potentially threshold-dependent
- F4. Genotype-enrichment hypotheses coexist with negative predictive-marker assessments
- F5. An undefined later-line role raises sequencing, alternative-treatment and tissue-work-up questions
- F6. Conditional approval optimism meets explicit dissent about evidentiary standards
- F7. The translational model is praised, with sample attrition limiting what it can answer
- F8. The connected ADC discussion questions whether target expression captures payload biology

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 13 | 11 | 9 | 8 | recorded | 3 |
| F2 | 8 | 9 | 8 | 6 | recorded | 3 |
| F3 | 7 | 8 | 7 | 6 | recorded | 3 |
| F4 | 7 | 7 | 6 | 6 | recorded | 3 |
| F5 | 8 | 10 | 6 | 5 | recorded | 3 |
| F6 | 2 | 2 | 1 | 2 | recorded | 2 |
| F7 | 16 | 14 | 10 | 6 | recorded | 3 |
| F8 | 10 | 5 | 2 | 2 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 0 | 0 | 5 | 2 | 14 | 0 | 8 posts and articles, 1 podcast or video | yes |
| F2 | 1 | 1 | 0 | 2 | 4 | 9 | 1 | 7 posts and articles, 1 podcast or video | yes |
| F3 | 3 | 1 | 0 | 0 | 3 | 8 | 0 | 6 posts and articles, 1 podcast or video | yes |
| F4 | 5 | 1 | 0 | 0 | 1 | 7 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F5 | 1 | 3 | 0 | 1 | 3 | 9 | 3 | 5 posts and articles, 1 podcast or video | yes |
| F6 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 post or article | yes |
| F7 | 14 | 1 | 0 | 0 | 1 | 16 | 0 | 9 posts and articles, 1 podcast or video | yes |
| F8 | 4 | 3 | 0 | 2 | 1 | 11 | 6 | 2 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Evaluation of objective response rate (ORR) based on investigator assessment: F1 (5 shared claims), F2 (2 shared claims), F3 (3 shared claims), F4 (3 shared claims), F5 (2 shared claims), F7 (1 shared claims)
- Secondary endpoints: F1 (6 shared claims), F2 (5 shared claims), F3 (4 shared claims), F4 (1 shared claims), F5 (1 shared claims), F7 (1 shared claims)
- Population and setting: F1 (3 shared claims), F4 (3 shared claims), F5 (5 shared claims), F7 (1 shared claims)
- The comparison: F1 (7 shared claims), F2 (1 shared claims), F3 (1 shared claims), F7 (2 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (6 shared claims), F3 (3 shared claims), F4 (1 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F7 (8 shared claims), F8 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F5. An undefined later-line role raises sequencing, alternative-treatment and tissue-work-up questions

An X post addressed the positioning of datopotamab deruxtecan in nonsquamous NSCLC following immunotherapy and chemotherapy.

Source: X thread, 2024-05-31.

### F7. The translational model is praised, with sample attrition limiting what it can answer

An X poster, described in the source as presenting ICARUS-LUNG01, addressed the study’s role in understanding ADCs.

Source: X thread, 2024-09-15.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 59 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 25 | Counts free |
| Speaker attribution for cited voices | 16 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Evaluation of objective response rate (ORR) based on investigator assessment | discussed | 10 | 8 |
| Secondary endpoints | discussed | 12 | 7 |
| Population and setting | discussed | 12 | 9 |
| The comparison | discussed | 10 | 3 |
| Safety and tolerability | discussed | 6 | 6 |
| Design and conduct | discussed | 13 | 9 |
| Histology-dependent activity and the value of replication | discussed | 10 | 9 |
| TROP2 expression, H-score and treatment selection | discussed | 9 | 8 |
| Genomic enrichment versus absent predictive alterations | discussed | 7 | 6 |
| Resistance mechanisms and longitudinal evidence | discussed | 11 | 5 |
| Later-line positioning, alternatives, sequencing and tissue work-up | discussed | 7 | 5 |
| Regulatory expectations and the evidentiary threshold | discussed | 2 | 1 |
| Appraisal of the translational research model | discussed | 10 | 7 |
| Antibody targeting, payload effects and biomarker uncertainty | discussed | 9 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 47 | 23 |
| Bluesky threads | 5 | 0 |
| YouTube | 2 | 1 |
| Podcasts | 1 | 1 |

- Screened window: 2024-04-20 to 2026-10-04
- Cited window: 2024-04-20 to 2026-10-04
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy
- Registry: NCT04940325 (https://clinicaltrials.gov/study/NCT04940325)
- Study IDs: 2023-505924-71-00 · 2020/3187 (CSET Number (Gustave Roussy ID))
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Collaborators: Daiichi Sankyo
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Active, not recruiting
- Enrollment: 100 (actual)
- Start: 2021-05-12 (actual)
- Primary completion: 2028-04 (estimated)
- Primary endpoint: Evaluation of objective response rate (ORR) based on investigator assessment (During treatment period, an average of 4 months)
- Intervention: DS-1062a (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on antibody–drug conjugate efficacy and safety in heavily pretreated non-small cell lung cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed are selected public discussions, not a representative sample of HCP opinion. Source totals and repost activity cannot be interpreted as numbers of independent clinicians or the prevalence of a view.
- Relevant commentary may be missing when it does not use the trial identifier or familiar study-name variants. Some potentially relevant passages were not fully evaluated, and additional presentation summaries are not represented.
- Some authors remain unnamed, and several video remarks cannot be assigned to a named participant. They cannot establish additional independent endorsements or disagreements.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Descriptions of presenting or involvement in ICARUS-LUNG01 are attributed source descriptions, not independently confirmed trial roles. Such appraisals should not be counted as external validation.
- Full protocol and exact-trial publication text were not available. Linked article descriptions provide qualitative context rather than a full evaluation of methods, results or mechanistic analyses.
- No exact DS-1062a regulatory label was available. Predictions and criticism about approval do not establish an agency decision or current regulatory status.
- Reported response proportions differ between sources, and one presentation relay does not identify its PFS comparator. These differences cannot be resolved from the sources reviewed.
- Organizational commentary and linked article descriptions are identified separately from HCP views; favorable organizational wording does not increase the certainty of efficacy, safety or biomarker conclusions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (59 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (14 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/icarus-lung01-nct04940325
- Agents: POST https://www.erudio.com/api/orders with {"report": "icarus-lung01-nct04940325", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=icarus-lung01-04940325

## Cite

Erudio Health. ICARUS-LUNG01 (NCT04940325): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/icarus-lung01-nct04940325

## Machine access

- JSON: https://www.erudio.com/reports/icarus-lung01-nct04940325.json
- Markdown: https://www.erudio.com/reports/icarus-lung01-nct04940325.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "icarus-lung01-04940325"}`